Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With Azacitidine in Advanced Myelodysplastic Syndrome-MedSci.cn

Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With Azacitidine in Advanced Myelodysplastic Syndrome

[Anonymous]

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020; 18 (2):

科室
- - 订阅+
  - 更多科室
工具
服务